BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gitto S, Gamal N, Andreone P. NS5A inhibitors for the treatment of hepatitis C infection. J Viral Hepat 2017;24:180-6. [DOI: 10.1111/jvh.12657] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
2 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect 2018;24:308.e5-8. [PMID: 28811242 DOI: 10.1016/j.cmi.2017.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
4 Kaddah MMY, Talaat W, El Demellawy MA. Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats. Biomed Chromatogr 2021;35:e5146. [PMID: 33893663 DOI: 10.1002/bmc.5146] [Reference Citation Analysis]
5 Mermer A, Keles T, Sirin Y. Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review. Bioorg Chem 2021;114:105076. [PMID: 34157555 DOI: 10.1016/j.bioorg.2021.105076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Kandangwa M, Liu Q. HCV NS5A hyperphosphorylation is involved in viral translation modulation. Biochem Biophys Res Commun 2019;520:192-7. [PMID: 31585734 DOI: 10.1016/j.bbrc.2019.09.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Jockusch S, Tao C, Li X, Chien M, Kumar S, Morozova I, Kalachikov S, Russo JJ, Ju J. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020;10:16577. [PMID: 33024223 DOI: 10.1038/s41598-020-73641-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
8 Nakamura H, Fujioka S, Terui T, Okuda S, Kondo K, Tamatani Y, Akagi Y, Komoda Y, Kinoshita W, Ito S, Maeda K, Ukaji Y, Inaba T. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. Bioorg Med Chem Lett 2020;30:127361. [PMID: 32738974 DOI: 10.1016/j.bmcl.2020.127361] [Reference Citation Analysis]
9 Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Lin L, Li H. Analysis of Clinical Trials of New Drugs for Liver Diseases in China. Drug Des Devel Ther 2021;15:3181-91. [PMID: 34321867 DOI: 10.2147/DDDT.S309964] [Reference Citation Analysis]
11 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
12 Warkad SD, Nimse SB, Song KS, Kim T. HCV Detection, Discrimination, and Genotyping Technologies. Sensors (Basel) 2018;18:E3423. [PMID: 30322029 DOI: 10.3390/s18103423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
13 von Felden J, Scheurich C, Yamamura J, Brainard DM, Mogalian E, Lohse AW, Schulze Zur Wiesch J. Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome. J Viral Hepat 2018;25:214-5. [PMID: 28783205 DOI: 10.1111/jvh.12768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Liu B, Gai K, Qin H, Liu X, Cao Y, Lu Q, Lu D, Chen D, Shen H, Song W, Zhang Y, Wang X, Xu H, Zhang Y. Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity. Eur J Med Chem 2018;148:95-105. [PMID: 29454920 DOI: 10.1016/j.ejmech.2018.02.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Choi JW, Kim JW, Nguyen LP, Nguyen HC, Park EM, Choi DH, Han KM, Kang SM, Tark D, Lim YS, Hwang SB. Nonstructural NS5A Protein Regulates LIM and SH3 Domain Protein 1 to Promote Hepatitis C Virus Propagation. Mol Cells 2020;43:469-78. [PMID: 32344996 DOI: 10.14348/molcells.2020.0018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Knops E, Sierra S, Kalaghatgi P, Heger E, Kaiser R, Kalinina OV. Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms. Genes (Basel) 2018;9:E343. [PMID: 29986475 DOI: 10.3390/genes9070343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Wagner R, Randolph JT, Patel SV, Nelson L, Matulenko MA, Keddy R, Pratt JK, Liu D, Krueger AC, Donner PL, Hutchinson DK, Flentge C, Betebenner D, Rockway T, Maring CJ, Ng TI, Krishnan P, Pilot-Matias T, Collins C, Panchal N, Reisch T, Dekhtyar T, Mondal R, Stolarik DF, Gao Y, Gao W, Beno DA, Kati WM. Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2018;61:4052-66. [PMID: 29653491 DOI: 10.1021/acs.jmedchem.8b00082] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
18 Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C, Morozova I, Kalachikov S, Kirchdoerfer RN, Russo JJ. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect 2020;8:e00674. [PMID: 33124786 DOI: 10.1002/prp2.674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]